Panther Biotech in deal to buy Alchemia Oncology

2 July 2015

USA-based Panther Biotechnology (OTC PINK: PBYA) has entered into an agreement to acquire Alchemia Oncology Pty Limited, a wholly owned subsidiary of Australian biotech firm Alchemia Limited (ASX: ACL).

Under the disclosed terms of the agreement, Panther and Alchemia have executed an agreement to complete the transaction within 120 days. Panther Biotechnology will acquire 100% of the Alchemia Oncology, assume certain liabilities and continue to develop the broad range of clinical drug candidates as targeted chemotherapeutics. The closing of the transaction is predicated on the successful listing of Panther Securities on Nasdaq.

Alchemia Oncology pipeline

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK